Physician profile
Kin Yip Chan
NPI 1891010112
$955.89
in general payments reported to CMS, 2019-2025
10 companies · $176 in 2025
The $176 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $185 · 2022: $230 · 2023: $261 · 2024: $104 · 2025: $176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $446 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $445.69 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $215.52 | 2021-2025 | Tremfya |
| Abbvie INC. | $211.30 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $151.44 | 2021-2024 | |
| Boston Scientific Corporation | $116.45 | 2022 | |
| Sun Pharmaceutical Industries INC. | $94.99 | 2023 | |
| Amgen INC. | $51.26 | 2023 | Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.61 | 2023 | Cyltezo |
| Strata Skin Sciences, INC. | $34.34 | 2025 | Xtrac |
| Incyte Corporation | $22.17 | 2025 | Opzelura |
| Galderma Laboratories, L.P. | $15.81 | 2024 | Aklief |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kin Yip Chan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.